Pharmaceutical

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.

Jul 24, 2024 - 04:00
Johnson & Johnson submits sNDA for SPRAVATO to treat depression
Johnson & Johnson is seeking approval for SPRAVATO for treatment-resistant depression with the submission of an sNDA to the US FDA.
Read the original article

Tags:

Previous Article

FDA approves Samsung Bioepis’ EPYSQLI as Soliris biosimilar

Next Article

Grünenthal gains Valinor Pharma and constipation drug Movantik

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

To prevent preeclampsia, experts push for broader blood pressure testing at home

To prevent preeclampsia, experts push for broader blood...

Apr 29, 2023

STAT+: Google will let health care customers test its generative AI model, ramping up rivalry with GPT-4

STAT+: Google will let health care customers test its g...

Apr 13, 2023

Opinion: How the government can help lower the price — not just the cost — of cutting-edge gene therapies

Opinion: How the government can help lower the price — ...

Nov 1, 2023